Evidence map›Paper›PMID 40863390›Full record

ReviewJournal of personalized medicine2025

Tailored Therapies in Addiction Medicine: Redefining Opioid Use Disorder Treatment with Precision Medicine.

Poorvanshi Alag, Sandra Szafoni, Michael Xincheng Ji, Agata Aleksandra Macionga, Saad Nazir, Gniewko Więckiewicz

Abstract readReview
In one paragraph

Review in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Poorvanshi AlagDepartment of Psychiatry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Sandra SzafoniDepartment of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Zabrze, Poland.ORCID 0000-0003-4980-5734
Michael Xincheng JiDepartment of Psychiatry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Agata Aleksandra MaciongaDepartment of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Zabrze, Poland.ORCID 0000-0003-0034-7373
Saad NazirDepartment of Psychiatry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Gniewko WięckiewiczDepartment of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Zabrze, Poland.ORCID 0000-0003-2404-393X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Opioid use disorder (OUD) is a chronic disease that remains difficult to treat, even with significant improvements in available medications. While current treatments work well for some, they often do not account for the unique needs of individual patients, leading to less-than-ideal results. Precision medicine offers a new path forward by tailoring treatments to fit each person's genetic, psychological, and social needs. This review takes a close look at medications for OUD, including methadone, buprenorphine, and naltrexone, as well as long-acting options that may improve adherence and convenience. Beyond medications, the review highlights the importance of addressing mental health co-morbidities, trauma histories, and social factors like housing or support systems to create personalized care plans. The review also explores how emerging technologies, including artificial intelligence and digital health tools, can enhance how care is delivered. By identifying research gaps and challenges in implementing precision medicine into practice, this review emphasizes the potential to transform OUD treatment. A more individualized approach could improve outcomes, reduce relapse, and establish a new standard of care focused on recovery and patient well-being.

Indexed as

addiction psychiatrybuprenorphineindividualized treatmentlong-acting medicationsmethadonenaltrexoneopioid use disorderpharmacological therapiesprecision medicine

Identifiers

PMID40863390
PMCPMC12387481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.